Combining a new drug with existing treatments for triple-negative breast cancer
Official title: Synergize a novel homologous recombination inhibitor with DNA damagingagents in TNBC
Funded at Creegh Pharmaceuticals, INC. · NIH-10760604 · Data updated 2026-11-12
This study is looking at a new way to help treat triple-negative breast cancer by using a special drug that makes cancer cells more vulnerable to standard treatments like chemotherapy and radiation, and if you have TNBC, you might be able to join the trials to see if this approach works better for you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Creegh Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | September 20, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $398,728 |
| NIH project number | 1R41CA281511-01A1 |
| Project ID | NIH-10760604 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer, particularly those who have not responded to standard treatments.
✕Less likely to help
Patients with other types of breast cancer that are hormone receptor-positive or HER2-positive may not benefit from this research.
What this research studies
This research investigates a novel approach to treating triple-negative breast cancer (TNBC), which lacks targeted therapies due to the absence of specific receptors. The study focuses on a new compound that inhibits a key DNA repair mechanism in cancer cells, making them more susceptible to existing treatments like chemotherapy and radiation. By combining this new drug with traditional therapies, the goal is to enhance treatment effectiveness and reduce the chances of resistance. Patients with TNBC may have the opportunity to participate in trials that explore this innovative treatment strategy.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with triple-negative breast cancer, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promise in combining DNA repair inhibitors with traditional cancer therapies, suggesting potential success for this novel approach.
Where this research is happening
-
Creegh Pharmaceuticals, INC.
Pittsburgh, United States Active
Researchers
- Principal investigator: Neumann, Carola Anke — Creegh Pharmaceuticals, INC.
- Study coordinator: Neumann, Carola Anke
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.